Claudin 4/CLDN4 is a member of the Claudins family and is one of the important junctional proteins of Tight Junctions (TJ). Accumulating researches in recent years reveals that Claudins play an important role in tumor immunotherapy and boasts a great potential for drug research (See more previous articles about Claudins family CLDN6; CLDN9; CLDN18.2). More and more studies revealed that CLDN4 functions as an effective target for tumor-targeted therapy and holds great potential for drug combination therapy (Read more about CLDN4).
For example, the researchers based on in vitro analysis found that CLDN4 regulates TNF-α signal pathway. Further experimental data showed that CLDN4 knockdown inhibited the growth and invasion in the xenograft mouse model. Moreover, CLDN4 combined with ITD-1 (TGF-β signal pathway inhibitor) achieve better results. In ovarian cancer, CLDN4 can mediate PI3K/Akt and EMT transcription factor Twist1; CLDN4 inhibits cell proliferation through JAK2/STAT3 signaling pathway; DNA demethylation of CLDN4 suppressed migration and invasion of HEp-2 cells, which was associated with MeCP2 recruitment HDAC1 etc.
To fully support researchers and pharmaceutical companies in their research on the CLDN4 targeted drug research in tumors, CUSABIO presents CLDN4 active protein (Code: CSB-MP005506HU) to assist you in your research on the mechanism of CLDN4 or its potential clinical value.
Excellent Bioactivity Validated by Functional ELISA
The high specifity was validated by western blot. CSB-MP005506HU is detected by Mouse anti-6*His monoclonal antibody.
Immobilized Human CLDN4 at 5 μg/ml can bind Anti-CLDN4 recombinant antibody (CSB-RA005506MA1HU), the EC50 is 29.56-50.75 ng/mL.
CUSABIO appreciates the critical role that you and our products play in research since many scientists are diligently pursuing their research to further scientific innovation and discovery. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.
